Preparation of a Klebsiella pneumoniae conjugate nanovaccine using glycol-engineered Escherichia coli.

ABSTRACT:

Background

Engineered strains of Escherichia coli have been used to produce bioconjugate vaccines using Protein Glycan Coupling Technology (PGCT). Nanovaccines have also entered the vaccine development arena with advances in nanotechnology and have been significantly developed, but chassis cells for conjugate nanovaccines have not been reported.

Results

To facilitate nanovaccine preparation, a generic recombinant protein (SpyCather4573) was used as the acceptor protein for O-linked glycosyltransferase PglL, and a glycol-engineered Escherichia coli strain with these two key components (SC4573 and PglL) integrated in its genome was developed in this study. The targeted glycoproteins with antigenic polysaccharides produced by our bacterial chassis can be spontaneously bound to

SUBMITTER: Liu Y 

PROVIDER: S-EPMC10163571 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature